针对 ERα DBD-LBD 接口与米托克桑,通过保护体退化破坏受体功能
Han Wang1, Yuxuan Luo2, Sandeep Artham3
1Department of Biochemistry and Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Molecular cancer therapeutics
|September 11, 2025
概括
一种新型药物 - - 线粒激素 (mitoxantrone) 针对雌激素受体 (ER) 独特的接口,抑制其功能并克服耐药性. 这一发现为乳腺癌治疗提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 雌激素受体 (ERα) 是光线乳腺癌的关键点.
- 目前的ER疗法面临阻力,需要新的策略.
- 在ER的DNA结合域 (DBD) 和带结合域 (LBD) 之间的接口尚未被探索.
研究的目的:
- 为了确定新的ER抑制机制.
- 为了找到针对ER DBD-LBD接口的配体.
- 开发克服内分泌疗法耐药性的策略.
主要方法:
- 计算查和功能测试.
- 生物物理,生物化学和细胞分析.
- 在体外和体外异种移植模型.
主要成果:
- 米托克桑 (MTO) 被确定为ER DBD-LBD接口的特定配体.
- MTO诱导ER的结构变化,细胞质再分配和蛋白质体降解.
- MTO强烈抑制野生型和耐药ER突变,抑制瘤生长.
结论:
- ER DBD-LBD接口是一个可服药的全位点.
- 通过破坏域间通信,MTO提供了一个新的治疗范式.
- 这种方法克服了传统的ER阻力机制.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Receptor Downregulation in MVBs
2.8K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.8K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Export of Misfolded Proteins out of the ER
5.0K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
5.0K
Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K
Targets for Drug Action: Overview
10.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.1K


